title: Cytokine-induced killer cell therapy for advanced pancreatic adenocarcinoma: A case report and review of the literature.
abstract: Patients with advanced pancreatic adenocarcinoma have a poor prognosis, and to date, no treatment method has had a significant impact on the disease. In general, the mean overall survival time of such patients receiving conventional chemotherapy and radiotherapy is <6 months. In the present case report, a patient with advanced pancreatic adenocarcinoma experienced a longer progression-free survival (PFS) of >19 months, following cytokine-induced killer (CIK) cell therapy. To the best of our knowledge, no study has previously described such a beneficial effect on patients only receiving CIK cell immunotherapy. Based on these findings, CIK cell therapy may be a potential treatment regimen that is capable of leading to an improved prognosis in certain patients with advanced pancreatic adenocarcinoma.
authors.affiliation: Department of Biotherapy, The Affiliated Tumor Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou 450003, P.R. China.
authors.forename: Wei
authors.initials: W
authors.lastname: Li
authors.forename: Lin Ping
authors.initials: LP
authors.lastname: Xu
authors.forename: Ling
authors.initials: L
authors.lastname: DI Zhao
authors.forename: Li
authors.initials: L
authors.lastname: Wang
authors.forename: Yong
authors.initials: Y
authors.lastname: Zhang
authors.forename: Quan Li
authors.initials: QL
authors.lastname: Gao
authors.forename: Ling
authors.initials: L
authors.lastname: Mai
keywords: advanced; cytokine-induced killer cells; pancreatic adenocarcinoma